ExpresSyn Cell Proteomic Research
Stage 1: Screening Ingredients for Maximum Effectiveness
Objective:
Identify the most effective ingredients for a specific clinical application through extensive in vitro testing performed at Metagenics' MetaProteomics® Nutrigenomics Research Center.
Step 1: Introduce selected nutrient factors into cell culture.
Nutrient factors may be introduced individually or in combinations.
First, we add natural ingredients to an in vitro cell-culture system. (Cell culture: the known production/activity profile of specific cells acts as a baseline from which changes can be observed.)
- Then (through various tests), we look at their impact on genetic expression and biochemical activity by observing changes in cell protein production/activity.
Step 2: Analyze changes in cell protein production/activity.
- Our research scientists and clinicians, who are among the world's leading experts in natural product research, evaluate the suitability of thousands of potential natural ingredients for inclusion in a formula.
- After paring down the candidates, hundreds of ingredients with a history of safe use are screened in a target cell-culture system (e.g., macrophages) to identify those with the greatest potential for beneficial results.
Stage 2: Determining Ingredient Synergy for Improved Bioactivity
Objective:
Test various combinations of potential formula ingredients from Stage 1 to identify the combination that delivers the highest level of synergistic activity at the lowest dose. (Synergy: the interaction of two or more agents or forces so that their combined effect is greater than the sum of their individual effects.)
- Because synergy between ingredients cannot be assumed, our researchers test combinations of the ingredients identified in Stage 1 to see if synergy will be observed.
- The same tests are run in the same target cell-culture system(s) used in Stage 1 to detect the desired levels.
- The combination and ratio of ingredients demonstrating the highest level of synergistic activity at the lowest dose is identified and selected for the next phase of the ExpresSyn Process.
Demonstration of Synergy with Kaprex™ - The First ExpresSyn Product
Safety evaluations Human ex vivo research Human clinical research